Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 5, 2008, Pages 1625-1633

  Glassberg, Marilyn K ^a   Elliot, Sharon J ^a   Fritz, Jason ^a   Catanuto, Paola ^a   Potier, Mylene ^c   Donahue, Roger ^a   Stetler Stevenson, William ^b   Karl, Michael ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE A; GELATINASE INHIBITOR; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; PROTEASOME;

ARTICLE; CELL CULTURE; CELL INVASION; CELL ISOLATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; GENE FUNCTION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

EID: 43249088754     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1283     Document Type: Article

References (42)

1. MK Glassberg Lymphangioleiomyomatosis Clin Chest Med 25 2004 573 582 vii
2. SC Juvet FX McCormack DJ Kwiatkowski GP Downey Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans Am J Respir Cell Mol Biol 36 2007 398 408
3. SA Pileri A Cavazza M Schiavina M Zompatori M Pederzoli M Goldfischer E Sabattini S Ascani G Pasquinelli F Bonetti TV Colby Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change Histopathology 44 2004 156 163
4. VJ Ferrans ZX Yu WK Nelson JC Valencia A Tatsuguchi NA Avila W Riemenschn K Matsui W Travis J Moss Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features J Nippon Med Sch 67 2000 311 329
5. U Berger A Khaghani A Pomerance MH Yacoub RC Coombes Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study Am J Clin Pathol 93 1990 609 614
6. MH Colley E Geppert WA Franklin Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis Am J Surg Pathol 13 1989 803 807
7. K Matsui K Takeda ZX Yu JC Valencia W Travis J Moss VJ Ferrans Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study Am J Respir Crit Care Med 161 2000 1002 1009
8. SR Johnson AE Tattersfield Lymphangioleiomyomatosis Semin Respir Crit Care Med 23 2002 85 92
9. A Tomasian MS Greenberg H Rumerman Tamoxifen for lymphangioleiomyomatosis N Engl J Med 306 1982 745 746
10. K Matsui K Takeda ZX Yu W Travis J Moss VJ Ferrans Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis Arch Pathol Lab Med 124 2000 267 275
11. V Lemaitre J D'Armiento Matrix metalloproteinases in development and disease Birth Defects Res C Embryo Today 78 2006 1 10
12. O Lenz SJ Elliot WG Stetler-Stevenson Matrix metalloproteinases in renal development and disease J Am Soc Nephrol 11 2000 574 581
13. WG Stetler-Stevenson AE Yu Proteases in invasion: matrix metalloproteinases Semin Cancer Biol 11 2001 143 152
14. EA Goncharova DA Goncharov A Eszterhas DS Hunter MK Glassberg RS Yeung CL Walker D Noonan DJ Kwiatkowski MM Chou Panettieri RA Jr VP Krymskaya Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM) J Biol Chem 277 2002 30958 30967
15. M Potier M Karl F Zheng SJ Elliot GE Striker LJ Striker Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens Am J Pathol 160 2002 1877 1885
16. GB Tremblay A Tremblay F Labrie V Giguere Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor β-β heterodimeric complex Mol Cell Biol 19 1999 1919 1927
17. M Potier SJ Elliot I Tack O Lenz GE Striker LJ Striker M Karl Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9 J Am Soc Nephrol 12 2001 241 251
18. M Potier M Karl SJ Elliot GE Striker LJ Striker Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice Am J Physiol Endocrinol Metab 285 2003 E1237 E1245
19. D Nonclercq F Journe JJ Body G Leclercq G Laurent Ligand-independent and agonist-mediated degradation of estrogen receptor-β in breast carcinoma cells: evidence for distinct degradative pathways Mol Cell Endocrinol 227 2004 53 65
20. TA Petrel RW Brueggemeier Increased proteasome-dependent degradation of estrogen receptor-β by TGF-β1 in breast cancer cell lines J Cell Biochem 88 2003 181 190
21. S Baldi M Papotti ML Valente M Rapellino E Scappaticci B Corrin Pulmonary lymphangioleiomyomatosis in postmenopausal women: report of two cases and review of the literature Eur Respir J 7 1994 1013 1016
22. EM Oberstein LE Fleming O Gomez-Marin MK Glassberg Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease J Womens Health (Larchmt) 12 2003 81 85
23. I Wahedna S Cooper J Williams IC Paterson JR Britton AE Tattersfield Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study Thorax 49 1994 910 914
24. SR Johnson AE Tattersfield Clinical experience of lymphangioleiomyomatosis in the UK Thorax 55 2000 1052 1057
25. G Finlay The LAM cell: what is it, where does it come from, and why does it grow? Am J Physiol Lung Cell Mol Physiol 286 2004 L690 L693
26. SR Johnson Lymphangioleiomyomatosis Eur Respir J 27 2006 1056 1065
27. J Matthews JA Gustafsson Estrogen signaling: a subtle balance between ER β and ER β Mol Interv 3 2003 281 292
28. DP McDonnell The molecular determinants of estrogen receptor pharmacology Maturitas 48 Suppl 1 2004 S7 S12
29. P Webb GN Lopez GL Greene JD Baxter PJ Kushner The limits of the cellular capacity to mediate an estrogen response Mol Endocrinol 6 1992 157 167
30. DM Lonard SY Tsai BW O'Malley Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins Mol Cell Biol 24 2004 14 24
31. Z Nawaz DM Lonard AP Dennis CL Smith BW O'Malley Proteasome-dependent degradation of the human estrogen receptor Proc Natl Acad Sci USA 96 1999 1858 1862
32. M Fan A Park KP Nephew CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-β Mol Endocrinol 19 2005 2901 2914
33. Y Tateishi Y Kawabe T Chiba S Murata K Ichikawa A Murayama K Tanaka T Baba S Kato J Yanagisawa Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor EMBO J 23 2004 4813 4823
34. CL Smith BW O'Malley Coregulator function: a key to understanding tissue specificity of selective receptor modulators Endocr Rev 25 2004 45 71
35. Z Nawaz BW O'Malley Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Mol Endocrinol 18 2004 493 499
36. F Yan X Gao DM Lonard Z Nawaz Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators Mol Endocrinol 17 2003 1315 1331
37. T Hayashi MV Fleming WG Stetler-Stevenson LA Liotta J Moss VJ Ferrans WD Travis Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM) Hum Pathol 28 1997 1071 1078
38. ML Corcoran Kleiner DE Jr WG Stetler-Stevenson Regulation of matrix metalloproteinases during extracellular matrix turnover Adv Exp Med Biol 385 1995 151 159
39. ML Corcoran RE Hewitt Kleiner DE Jr WG Stetler-Stevenson MMP-2: expression, activation and inhibition Enzyme Protein 49 1996 7 19
40. ML Corcoran MR Emmert-Buck JL McClanahan M Pelina-Parker WG Stetler-Stevenson TIMP-2 mediates cell surface binding of MMP-2 Adv Exp Med Biol 389 1996 295 304
41. MR Emmert-Buck HP Emonard ML Corcoran HC Krutzsch JM Foidart WG Stetler-Stevenson Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex FEBS Lett 364 1995 28 32
42. MN VanSaun LM Matrisian Matrix metalloproteinases and cellular motility in development and disease Birth Defects Res C Embryo Today 78 2006 69 79